Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Receivables (2020 - 2023)

Rocket Pharmaceuticals' Receivables history spans 4 years, with the latest figure at $50000.0 for Q4 2023.

  • For Q4 2023, Receivables changed N/A year-over-year to $50000.0; the TTM value through Dec 2023 reached $50000.0, changed N/A, while the annual FY2023 figure was $50000.0, N/A changed from the prior year.
  • Receivables for Q4 2023 was $50000.0 at Rocket Pharmaceuticals, down from $900000.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.6 million in Q2 2020 and bottomed at $50000.0 in Q4 2023.
  • The 4-year median for Receivables is $1.0 million (2021), against an average of $835714.3.
  • The largest annual shift saw Receivables plummeted 93.75% in 2021 before it decreased 10.0% in 2022.
  • A 4-year view of Receivables shows it stood at $1.1 million in 2020, then tumbled by 90.91% to $100000.0 in 2021, then skyrocketed by 800.0% to $900000.0 in 2022, then tumbled by 94.44% to $50000.0 in 2023.
  • Per Business Quant, the three most recent readings for RCKT's Receivables are $50000.0 (Q4 2023), $900000.0 (Q1 2022), and $100000.0 (Q2 2021).